The senior vice president of research at Vaxxinity discussed recently published trial findings on a novel vaccine that targets Alzheimer disease and triggers the production of antibodies against toxic amyloid-ß peptides. [WATCH TIME: 9 minutes]
Jean-Cosme Dodart, PhD
Advertisement
Senior vice president of preclinical research and development at Vaxxinity.
Articles by Jean-Cosme Dodart, PhD
The senior vice president of research at Vaxxinity talked about research for a potential vaccine for migraine prevention presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 MG0020 Trial Highlights Success of Self-Administered Rozanolixizumab for Generalized Myasthenia Gravis
2
Efgartigimod Treatment for CIDP Leads to Increased Spending, Study Shows
3
Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials
4
Open-Label Extension Highlights Continued Therapeutic Benefit of Nipocalimab in Patients Transitioning From Placebo
5
